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Abstract Merkel cell carcinoma (MCC) is an aggressive
neuroendocrine tumor of the skin with a rising inci-
dence. MCC has metastatic potential regardless the size
of the primary tumor and a 5-year disease associated
mortality rate is 46 %. Surgery and radiation are the
mainstays of management for primary MCC. There is
no evidence-based effective chemotherapy for recurrent
or metastatic diseases to date. In-depth mechanistic studies in
MCC have uncovered important cellular events and the asso-
ciation with a polyomavirus, which has provided direct evi-
dence for molecular targeted and immunotherapy. Further
perspective studies and clinical trials are warranted to provide
reliable evidence of possible pitfalls and effectiveness of
molecular targeted immunotherapy alone or in combination
with chemotherapy in MCC.
Keywords Merkel cell carcinoma .Merkel cell
polyomavirus . Immunosuppression . Sentinel lymph node
biopsy . Immune therapy .Chemotherapy .Radiation therapy .
Signaling pathway
Introduction
Merkel cell carcinoma (MCC) is a rare neuroendocrine
tumor of the skin with a rising incidence and an ag-
gressive behavior. It was first described as trabecular
carcinoma in 1972 by Toker [1]. The name of MCC
was adopted because the neoplasm was originally
thought to arise from the Merkel cells of the epidermis
[2]. However, recent observations question the notion
and propose that pluripotent dermal stem cells are the
origin of MCC [3]. Interestingly, early B cell differen-
tially is also identified in MCCs [4]. Currently, surgical
excision and radiotherapy are the mainstays of manage-
ment for primary MCCs. Although one-third of the
patients will eventually develop distant metastasis, there
is no evidence-based effective chemotherapy for recur-
rent and metastatic disease with a proven survival ben-
efit. Recently, a causal link between the Merkel cell
polyomavirus (MCV) and the pathogenesis of MCC,
together with both MCV dependent and independent
cellular events, holds the promise for mechanism-based
and disease specific therapy. This is a review of the
epidemiology, immune targets and therapy of MCC with
a focus on recent literature.
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The annual incidence of MCC is 0.6 per 100,000 persons and
is increasing (approximately 1,600 new cases per year in the
US) [5•]. In Australia, between 1986–2001, the age-adjusted
incidence rose at an annual increase of 8%, as compared to the
3 % rise in cutaneous melanoma [6]. In the Netherlands, the
incidence per million increased from 1.7 in 1993–1997 to 3.5
in 2003–2007 [7]. This rising incidence is partly due to
increased awareness and improved diagnostic techniques, es-
pecially the introduction of cytokeratin 20 immunostaining.
The median age at diagnosis is 76.2 years for women and
73.6 years for men. Only 4 % of patients are diagnosed at 49
years or younger, and it is exceedingly rare in children with
only scattered case reports [8•]. The incidence of MCC is
approximately 11-fold to 13-fold greater in patients with
AIDS and 5-fold to 10-fold greater for people with a solid
organ transplant [9]. According to the National Cancer Data
Base (NCDB), the majority of MCCs present with local
disease (66 %), followed by nodal disease (27 %) and meta-
static disease (7 %). However, the percentage of patients with
nodal disease is higher if a sentinel lymph node biopsy
(SLNB) is performed. Patients with local disease had a 64 %
relative survival at five years, as compared to 39% in regional
nodal disease and 18 % in metastatic disease [10••].
UV Exposure and Immunosuppression
There is a positive association between geographic UVB
radiation indices and age-adjusted MCC incidence among
white patients [6]. Moreover, the incidence of MCC was 100
times greater in patients with a history of PUVA treatment
than that in the general population [11]. According to data
collected from the Surveillance, Epidemiology and End Re-
sults (SEER) from 1973 to 2006, 94.9 % of patients were
white with tumors in the head and neck region. African
Americans represented only 1 % of patients, with tumors
arising more frequently on the lower extremities [8•]. Similar
to melanoma, another UV-induced tumor, MCC may have a
predilection for the left face and arms [12]. Nonetheless,
MCCs also occur on non-sun-exposed areas such as on
the buttocks. Immunosuppression is a known risk factor
for the development of MCC. More specifically, immu-
nosuppressed patients with T-cell dysfunction, i.e., solid
organ transplant recipients, AIDS patients and chronic
lymphocytic leukemia patients are at an increased risk
of developing MCC. Further observations highlighting
the importance of the immune system are cases of MCC
regressing following improvement in immune function
and sudden clearance of MCC after recognition by the
immune system [13, 14].
Merkel Cell Polyomavirus (MCV)
Polyomaviruses are small, nonenveloped, double-stranded,
circular DNA viruses. The initial association of MCV and
MCC was described by Chang and colleagues in 2008 using
Digital Transcriptome Subtraction and cDNA libraries created
from MCC tumor mRNA [15]. Since then, several groups
have independently verified an association between MCV
and MCC.
MCV Prevalence
In the general population, MCV seroprevalence is 9 % in
children younger than four years of age and increases to
35 % by 4–13 years of age [16•]. Using immunoassays,
Tolstov et al., found that 80 % of healthy North American
adults (blood donors) showed evidence for past MCV expo-
sure. Consistent with this, MCV was detected in 80 % of
cutaneous swabs from healthy volunteers, suggesting it may
be a common inhabitant of the human skin [17]. Despite this
prevalence, extensive efforts sought to find an association
between MCVand other diseases have largely failed [16•].
Pathogenesis
Although MCV is strongly associated with MCC and many
studies support its role in pathogenesis, the presence of virus is
not sufficient to induce MCC carcinogenesis. As with other
cancer-associated viruses, additional cellular events together
with loss of immunosurveillance are postulated to contribute
to MCC tumor development. Thus, although infection with
MCV is common, MCC is still a very rare cancer. MCV
encodes a large T tumor antigen (LT) and a small antigen
tumor (sT), which both play a role in MCC pathogenesis by
targeting several tumor suppressor genes. (18). Since the
discovery of MCV, both LT and sT have been used as bio-
markers, aid in predicting prognosis, to gauge therapeutic
response and in the detection of recurrence ofMCC. However,
the pathogenic role of MCV needs further elucidation. For
example, the dependence of MCC cell lines on LT and/or sT
differs. Similarly, studies have yielded conflicting results in
terms of the presence of MCV and viral load on clinical
implications in MCC [18].
Therapeutic Targets
Host Immune System
Epidemiologic data suggest a strong link between MCC and
the immune system. MCV infection induces a humoral and
cellular immune response, notably, while immune responses
to the viral capsid proteins are present in most people, immune
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responses to the transforming early genes, i.e., LT and sT, are
only present in MCC patients. A transcriptome study of MCC
tumors demonstrates a positive association between improved
outcomes and robust infiltration of CD8+ lymphocytes in the
tumor [19]. Moreover, a recent study has found the MCV-
specific T cells express high levels of immune checkpoint
receptor PD1 and Tim-3, which provide direct evidence of
immune therapy in MCCs [5•].
Aberrant Signaling Pathways in Tumor Cells
Cytotoxic activity by chemotherapy has been the main-
stay in the management of advanced MCC. However, it
failed to demonstrate improved survival and is associat-
ed with a high mortality rate [20, 21]. Until recently,
aberrations in signal transduction contributing to the
oncogenic phenotype of MCC were largely unknown.
However, in-depth mechanistic studies are necessary to
provide the rationale for mechanism-based antitumor
therapy. Interrogation of MCC tumors for mutations of both
tumor suppressor genes and oncogenes, such as p53, PTEN,
Ras, B-RAF, c-kit, β-catenin, which are frequently mutated
and dysregulated in many cancers, have failed to reveal a
consistent significant role for any of the genes in MCC [22].
More specifically, in search of receptor tyrosine kinase (RTK)
involvement in MCC tumorigenesis (providing a rationale for
the use of targeted therapies), studies have found variable
expression of c-kit, VEGFs, PDGFα and PDGFβ in MCCs
compared to normal skin. Intriguingly, one study has shown
that the MAP kinase pathway is silent (as demonstrated
by lack of pathway activation and no ERK phosphory-
lation) in the majority of MCCs examined [23]. Recent-
ly, the PI3K/AKT and mTOR pathway, the most com-
mon dysregulated pathway in human cancer, was found
to be up-regulated in MCCs, despite low mutation rates
of PI3K/Akt detected [24•, 25, 26]. Collectively, acti-
vated pathways will be potential targets in mechanism-
based therapy.
Staging and Treatment
The American Joint Committee on Cancer TNM Staging
Classification should be used for a comprehensive stag-
ing system of MCC patients. MCC localized to the skin
are staged according to the size of the primary tumor-
stage I (≤ 2 cm) or stage II (>2 cm). The A and B
subclassification is based on pathological versus clinical
evaluation of lymph nodes. Stage III is a regional nodal
disease with stage IIIA being positive lymph nodes
identified by pathology and stage IIIB being clinically
or radiological positive lymph nodes. Stage IV is meta-
static disease outside of the regional nodal basin.
Surgery
Wide Local Excision vs. Mohs Micrographic Surgery
Based on the current National Comprehensive Cancer Net-
work (NCCN) guidelines, wide local excision is the mainstay
treatment for stage I and stage II diseases. Wide local excision
with a 2 to 3 cm margin is recommended, except for the head
and neck region where narrow margins may be acceptable.
There is limited data regarding the local recurrence rate be-
tween wide local excision andMohs surgery. It is important to
note that the clinical presentations for locoregional recurrence
are satellite and in-transit metastases. Therefore,Mohs surgery
is challenged in MCC as per continuitatem invasion is the
prominent cause for recurrences. Thus, the central portion of
the tumor is recommended for permanent sections if Mohs
micrographic surgery is used.
Sentinel Lymph Node biopsy (SLNB
SLNB is recommended in both Stage I and Stage II diseases,
due to the metastatic potential of MCC (10). A study by
Bichakjian, et al., found a SLNB positivity rate of 20 %-
30 % in patients with Stage I disease and clinically negative
node [27]. Furthermore, SLNB-negative patients carry a better
prognosis than patients with only clinical nodal evaluation. In
a study including 5,823 MCC patients, those with localized-
disease, as well as pathologically negative nodes on SLNB
had a significantly better outcome than those undergoing only
clinical nodal assessment [10••]. SLNB results in more accu-
rate staging, and if positive, nodal treatment decreases recur-
rence. However, SLNB is not recommended if it will not
change management or if the prognostic data does not result
in a change of management of the patient. Although studies
comparing radiation alone with complete lymph node dissec-
tion yields similar outcomes, the most common practice for
MCC patients with a positive SNL is complete lymph node
dissection in conjunction with radiation.
Radiation
Fractionated
Standard postoperative treatment consists of 50–60 Gy given
in conventional equal fractions over a 5–6 week period [28].
Although adjuvant radiation therapy is controversial for stage
I and stage II MCC, it is recommended by NCCN for ad-
vanced local and regional disease. All published studies on the
efficacy of adjuvant radiation have been retrospective.Most of
these studies have demonstrated an increase in locoregional
control and improvement in disease-free survival with post-
operative radiation therapy [29], but not in all cases [30, 31]. A
literature review by Medina-Franco et al., demonstrated a
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significantly decreased rate of local recurrence (10.5 %) with
adjuvant radiotherapy compared to surgical excision alone
(52.6 %) [32]. Two recent studies have also demonstrated
improved overall survival with postoperative radiation thera-
py [27, 33]. Elective radiation therapy to regional nodal basins
has been used to decrease the regional recurrence rate. A
randomized trial of elective nodal irradiation versus observa-
tion in early stage MCC was terminated early; however,
analysis of accrued patients revealed a significant decrease
in regional recurrence in the radiotherapy arm (0 % vs.
16.7 %) [34].
Radiotherapy may be used alone for MCC when the
tumor is inoperable or when the patient refuses surgery.
Interestingly, no statistical difference was found in over-
all and disease-free survival in 25 patients with primary
MCC treated with radiotherapy alone as compared to
patients treated with surgery followed by radiotherapy
[32]. In evaluation of radiation as a monotherapy for
lymph node-positive MCC, Fang et al., found that there
was no difference with regard to overall survival between
radiotherapy and completion lymphadenectomy [35]. A sim-
ilar control rate has been reported by Sundaresan et al., a
definitive radiation treatment of 30 regions (primary and
regional nodes) resulted in a two-year local control rate of
89 % [36].
Surface-mold Computer-Optimized Brachytherapy
In-transit metastases (Stage IIIB disease) usually develop in
the extremities and clinically appear to be violaceous nodules
or palpable subcutaneous nodules. Because in-transit metas-
tases are typically multifocal, conventional external-beam
radiation therapy can be technically challenging. Surface-
mold computer-optimized brachytherapy (SMBT) allows
delivery of high doses of radiation achieving an effec-
tive local control with limited toxicity. A recent report
by Wang et al., of ten MCC patients and a total of 152
in-transit metastases were treated with high dose radia-
tion (12 Gy in two equal fractions of radiation). Al-
though high dose SMBT brachytherapy did not alter the
disease course with respect to overall survival, it pro-
vided a good in-field control rate of 99 % [35].
Emerging Radiation Techniques
A single fraction of high-dose radiation has been showed to
stimulate lymph node priming and reduce primary and meta-
static tumors in a CD8 T-cell – mediated fashion in a melano-
ma mouse model [37]. Treatment with high doses and fewer
fractions has been safe and effective in palliation, as well as
more convenient for patients. In a study by Nghiem’s group
including 15 MCC patients treating with a single fraction of
8 Gy to lymph node or internal organ metastases, they
reported 11 complete and four partial responses in a median
follow-up of five months [38]. No significant side effects were
observed. This palliative regimen is particularly attractive to
elderly patients who depend on transportation, with the pos-
sibility of combining treatment of symptomatic lesion with a
potential stimulation of immune response to MCC. However,
long-term follow-up data is needed before it becomes a main-
stream approach.
In sum, radiation is beneficial as an adjuvant therapy for
advanced local and regional disease. However, questions re-
garding the role of radiation in early stage disease with neg-
ative SLNB and the potential for shortening radiation courses
with higher dose per fraction remain.
Chemotherapy
Systemic Chemotherapy
Although MCC is considered to be chemotherapy sen-
sitive with initial efficacy in disease regression, resis-
tance usually develops after the first 2–3 cycles, and it
is associated with significant toxicity. In a retrospective
study, 69 % of patients with locally advanced disease
and 57 % with metastatic disease responded to first-line
chemotherapy. However, survival was limited to an av-
erage of 24 months with locally advanced and nine
months with metastatic disease; 7.7 % of deaths were
associated with drug related toxicity [20, 21]. The most
common cytotoxic agents used are platinum with or without
etoposide. Others are anthracyclines, antimetabolites, cyclo-
phosphamide, etoposide and platinum agents alone or in
combination.
Isolated Limb Perfusion and Infusion
Isolated limb perfusion was developed in the 1950s to
treat in-transit, unresectable melanoma of the extremi-
ties. The advantage is local delivery of chemotherapy to
minimize systemic side effects. Subsequently, isolated
limb infusion (ILI) was adopted in the early 1990s
because it is safer and less invasive. Available data are
largely based on extrapolation from the melanoma liter-
ature. Wong et al., recently reported their experience of
over 100 ILI, including 79 melanoma patients and three
MCC patients [39]. Actinomycin-D and melphalan were
used and was dosed based on limb volume. At three
months, the initial complete response rates for upper
extremity and lower extremity melanoma are 42 % and
35 %, respectively. No significant side effects were
reported. Although not commonly used for local and
regional control of MCC, this treatment modality may
prove beneficial in select MCC patients and further
study is warranted.
Curr Derm Rep (2014) 3:46–53 49
Immunotherapy
Cytokine Therapy
It is known that cytotoxic T-cell activation is required for
antitumor activities. Cytokines are grouped as type I which is
associated with cytotoxic T-cell activation, while type II is
associated with antibody formation [40]. Although both type I
and type II interferon induces apoptosis in MCV positive MCC
cells in vitro, the clinical application of interferon α in two
MCV positive MCC patients failed to demonstrate therapeutic
efficacy [41, 42]. Of note, intralesional interferon β application
shows early success in local control; however, further studies
are needed. An ongoing phase II clinical trial is testing
intralesional delivery of IL-12 plasmid followed by electropo-
ration to promote Th1 response and increase interferon γ
expression (http://clinicaltrials.gov/show/NCT01440816).
Adoptive Immunotherapy
This approach remains investigational, but it is associatedwith
long-term remission. It involves harvesting tumor infiltrating
lymphocytes or peripheral T cells, followed by ex vivo ex-
pansion. Further manipulation of tumor-reactive T-cells and
co-administration with NK cells or dendritic cells and/or
vaccine has been explored in melanoma. Hopefully MCC
specific clinical trials are forthcoming soon. Additionally,
the discovery of MCV renders a potential target for develop-
ing viral antigen directed immunotherapy or vaccine. A Phase
I/II clinical trial is current recruiting metastatic MCC patients
who will be treated with autologous T cells and IL-2
(aldesleukin) (http://clinicaltrials.gov/show/NCT01758458).
Transgenic T-cell receptor based therapy and soluble T-cell
antigen receptor (STAR) reagent has been also tested in other
advance solid tumors.
Immune Checkpoint Inhibition
Comprehension of immune system modulation by targeting
co-inhibitory and co-stimulatory receptors has become a
promising new approach of immunotherapy for cancer.
CTLA-4 is an important negative regulator of T-cell-
mediated antitumor responses. Development of blocking an-
tibodies directed against CTLA-4, such as ipilimumab, has
opened a new era in the field of immunotherapy for cancer.
Inspired by the success in melanoma, a randomized clinical
trial is currently enrolling in Europe with ipilimumab versus
observation following surgical resection of MCC
(EUDRACT: 2013-000043-78). Similarly, another new mol-
ecule has been generated against programmed death-1 (PD1;
CD279), an inhibitory receptor that down-regulates T cell
function following engagement of PD1 ligand (PDL1) that is
exclusively expressed on tumor cells. While CTLA-4 is only
expressed in T cells, PD-1 expression is not only found in T
cells, but also inducible in B-cell and natural killer (NK) cells.
In order to block the inhibitory PD1 pathway, anti-PD1 and
anti-PDL1 monoclonal antibodies have been generated with
reportedly improved safety profiles and fewer side effects than
as compared to anti-CTLA-4 antibodies. It is promising that
another immune checkpoint modulating antibody 4-1BB
(CD137) is currently in clinical development.
IMGN901 (BB10901, huN901-DM1)
CD56 is expressed on virtually all MCC tumors. IMGN901 is
a novel CD56-targeting anti-cancer agent that consists of a
potent cytotoxic agent, DM1, which is attached to a CD56-
binding monoclonal antibody, huN901, using an engineered
linker. Once bound to CD56, IMGN901 is internalized into
the cancer cell and the DM1 is released, killing the cell via
inhibition of the polymerization of tubulin. There is an ongo-
ing Phase I clinical trial evaluating IMGN901 in CD56 ex-
pressing tumors, including MCC (http://clinicaltrials.gov/
show/NCT00346385).
Molecular Targeted Therapy
In parallel, efforts have showcased the efficacy of targeted
therapy inhibiting disease-driving mutations of the BRAF and
MAPK pathway inhibitors in melanoma.
PI3K Inhibitors
Up-regulation of PI3K/Akt has been demonstrated in
two independent studies [25, 26], providing a rationale
for inhibition of PI3K in MCC. There are several on-
going PI3K inhibitor clinical trials; however, none of
them is MCC specific.
mTOR Inhibitors
The mammalian target of rapamycin (mTOR) pathway is a
master regulator of protein synthesis and is frequently found
to be dysregulated in human cancers. Likewise, mTOR is
found to be up-regulated in MCC (18). The mTOR resides
in two complexes, mTOR complex1 (mTORC1) and mTOR
complex 2 (mTORC2), which execute distinct cellular tasks.
Rapamycin and its analogues are allosteric inhibitors via
mTORC1 inhibition. Sirolimus, temsirolimus, everolimus
and deforolimus are also members of this family. Underscored
by the clinical inefficacy of allosteric inhibitors, more potent
inhibitors of the active site of mTOR kinase, such as PP242,
WYE-354, Ku-0063794 and INK128, have been developed.
INK128 (MLN0128) is currently open for Dose Escalation
study in patients with advanced solid tumors based on its high
potency (http://clinicaltrials.gov/show/NCT01058707).
50 Curr Derm Rep (2014) 3:46–53
Apoptosis Induction
Decreased apoptosis is evident in MCC regardless of
MCV status. YM-155 has been shown to down regulate
survivin expression and promote apoptosis in MCC
xenograft tumors [43] Phase II clinical trials of YM-
155 in combination of other agents have been complet-
ed for other tumor types. Other apoptotic inhibitors,
such as ABT-263, have also shown some clinical effi-
cacy as a single agent or in combination [44]. A Bcl-2
antisense has shown to halt tumor growth in MCC
xenograft animal models, however, a Bcl-2 antisense,
Genasense, fails to show therapeutic efficacy in MCC
[45–47].
Receptor Tyrosine Kinase Inhibitors
Imatinib
Although mutation in c-kit and PDGFR are rare events in
MCCs, successful MCC patients treated with imatinib have
been reported [48–50]. However, a Phase II clinical trial
concluded that most MCCs progressed during the one or
two cycles of treatment [51]. Therefore, there is limited clin-
ical application of Imitinib in MCC.
Pazopanib
Pazopanib targets both VEGFR and PDGFR, which are
overexpressed in a subset of MCC [49]. In one report,
pazopanib resulted in a complete resolution of primary
tumor of the scalp disease and a partial response in lung
metastases [52]. Currently, a Phase II clinical trial for
metastatic MCC is open in Europe (EUDRACT Num-
ber: 2011-003226-27).
Octreotide
Octreotide is a potent analog of somatostatin and has anti-
proliferative and anti-angiogenic effects in neuroendocrine
tumors. Overexpression of somatostatin receptor 2 has been
demonstrated at the mRNA level in 90 % MCC [53]. More-
over, a radiolabeled somatostatin analogue containing
the active octapeptide of somatostatin (90Y-DOTATOC)
induces remission in a metastatic MCC [54]. Further-
more, synchronous use of 177 lutetium-labeled somato-
statin analogs and radiosensitizing chemotherapy in a
MCC patient with visceral metastasis demonstrates the
feasibility of applying this technique in metastatic MCCs.
Based on this, a 177Lutetium-DOTA-Octreotate therapy in
somatostatin receptor-expressing Neuroendocrine Neoplasms
is recruiting patients (http://clinicaltrials.gov/show/
NCT01237457).
Conclusion
A hallmark of human cancer is heterogeneity. At the genetic
level, cancer is a reflection of the complex series of changes
resulting in the activation of oncogenes coupled with inacti-
vation of tumor suppressor genes. However, targeted therapy
at the gene level remains a challenge, as there is a distinction
between driver mutations that can propel the development of
cancer and driver mutations on which the cancer cell contin-
ually depends. Moreover, secondary resistance often de-
velops, as observed in melanoma with BRAF inhibition.
Given individual variation in the host immune system as
manifested by disease outcome, response to therapy and abil-
ity to metastasize, combination therapy with immunomodula-
tor becomes crucial. Recent advances in targeted therapy and
immunotherapies in the treatment of metastatic melanoma
have instigated application of a similar approach to other
tumor types, including MCC. Therefore, researchers await
Phase I and Phase II studies with great interest for MCC, as
there is a great need for improved therapy.
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